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Abstract 
Recently, there has been an intense discussion about the issue of fibroid and uterine 
morcellation in relation to the risk of unrecognized uterine sarcoma spread. Morcellation 
can negatively influence the prognosis of patients, and transecting the specimen into pieces 
prevents the pathologist from performing proper disease staging. Many societies have 
published their statements regarding this issue. The European Society for Gynecological 
Oncology has established a working group of clinicians involved in diagnostics and treatment 
of oncogynecological patients to provide a statement from the oncological point of view. 
Leiomyosarcomas and undifferentiated endometrial sarcomas have generally dismal 
prognosis, whereas low-grade endometrial stromal sarcomas and adenosarcomas have 
variable prognosis based on their stage. A focus on the detection of patients at risk of having 
a sarcoma should be mandatory before every surgery where morcellation is planned by 
evaluation of risk factors (African American descent, previous pelvic irradiation, use of 
tamoxifen, rapid lesion growth particularly in postmenopausal patients) and exclusionof 
patientswith any suspicious ultrasonographic signs. Preoperative endometrial biopsy should 
be mandatory, although the sensitivity to detect sarcomas is low. An indication for 
myomectomy should be used only in patients with pregnancy plans; otherwise en bloc 
hysterectomy is preferred in both symptomatic and postmenopausal patients. Eliminating 
the technique of morcellation could lead to an increased morbidity in low-risk patients; 
therefore, after thorough preoperative evaluation and discussion with patients, morcellation 
still has its place in the armamentarium of gynecologic surgery. 
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A recent debate has emerged on the use of fibroid and uterine morcellation. In short, the 
view argues that power morcellators increase the risk of unrecognized uterine sarcomas 
spreading.1 In the US it was estimated that the risk of finding an unexpected sarcoma in a 
patient undergoing surgery for presumed fibroid tumors is about 1 in 352 cases.2 In response 
to these reports the US Food and Drug Administration (FDA) issued a warning against power 
morcellation. The consequences of the FDA statement are profound, leading to a shift from 
minimally invasive surgery to open surgery as a means to improve oncological safety.  
The European Society for Gynecological Oncology (ESGO) has established a working group of 
clinicians involved in diagnostics and treatment of oncogynecological patients. Core 
questions about morcellation have been formulated and discussed within the group. A 
summary and consensus statement has been endorsed by the working group in order to give 
relevant figures and arguments for and against morcellation techniques. 
 
Introduction 
The main issue is the risk of an undiagnosed sarcoma while treating a patient with presumed 
benign uterine fibroid tumors. Some reports have observed a worse prognosis of patients 
with uterine sarcoma who underwent power morcellation during surgery because such a 
procedure may cause the spread of cancer cells to the abdominal cavity of women, 
especially in leiomyosarcomas.3;4 A complete resection and achievement of clear margins 
are another prognostic factors aggravated by morcellation.5 
Fibroids are common benign uterine tumors affecting approximately 70% of the female 
population. Treatment is required in about 15-30% of female patients6 and in 2013 
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hysterectomy was indicated in about 450 000 patients in Europe annually.7 A misdiagnosis 
concerns not only radical treatment of fibroid tumors but also other therapeutic options, 
such as uterine artery embolization and magnetic resonance imaging (MRI)-guided focused 
ultrasound surgery.8 
Uterine sarcomas are rare tumors. The incidence rates are retrieved from retrospective data. 
In European countries the incidence rates (based on 2011 data) range from 0.35-1.53/100 
000, representing 1 332-5 824 women in the overall female population of 380 686 199.9 
Because most of the sarcomas develop from mesenchymal tissue, it is difficult to diagnose 
such malignant tumors preoperatively.  
Oncogynecological remarks on prognosis and behavior of different histopathological 
subtypes based on the last WHO classification10 are listed below: 
1. Leiomyosarcomas (LMS) are usually found in postmenopausal women with mean 
age of 55 years. They can mimic leiomyomas and constitute about 60-70% of all 
sarcomas. Their prognosis is poor, even in stage I, with a recurrence rate from 53-
71%. The 5-year survival rate for LMS is about 41%.11;12   
2. Atypical smooth muscle tumors of uncertain malignant potential (STUMP) have a 
highly favorable prognosis in that they exhibit only some suspicious histological 
features. 
3. Low-grade endometrial stromal sarcomas (LGESS) have a generally favorable 
prognosis with stage being the strongest prognostic factor. ESSs make up 
approximately 20-30% of all sarcomas. For stage I, the 5-year survival rate is about 
90% vs. 50% for stage III or IV.13  
 5 
 
4. Undifferentiated endometrial sarcomas (UESs), also referred to as high-grade 
endometrial stromal neoplasms, present at stages III and IV in about 60% of all These 
UESs exhibit a highly aggressive biology and the prognosis of these patients is 
dismal.14  
5. Adenosarcomas (AS) are rare tumors that usually arise as polypoid lesions and are 
thought to have a favorable prognosis. These tumors have a tendency to fill and 
distend the uterine cavity. About 25% of patients with AS will die from the disease. 
The incidence rate is about 5% of all sarcomas.15  
How should we preoperatively identify the patient group at high risk for uterine sarcomas 
requiring an en bloc resection? 
The need for improvements in preoperative workup is essential insofar as this stage could 
further decrease the number of unsuspected sarcomas.  
Risk factors for uterine sarcoma are ethnic background (women with uterine sarcomas are 
more likely to be of African American descent), previous pelvic irradiation, use of tamoxifen,  
past history of hereditary retinoblastoma, age above 50 and rapid lesion growth, particularly 
in postmenopausal patients.  
Ultrasonographic examination can reveal indirect signs, including oval lesions, central 
necrosis, high central vascularization, fast growth, absence of calcifications and 
shadowing.16-18 Measurement of serum LDH has been proposed as a potential marker, 
largely because it may be elevated in leiomyosarcoma. However, its low specificity limits its 
use because LDH may be elevated in simple leiomyomas.19 Another imaging method that 
could help to detect a potential sarcoma is diffusion-weighted MRI combined with serum 
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levels of LDH, but costs and access may be limiting factors in some countries.20-22 
Nevertheless, the specificity of imaging to accurately predict a sarcoma before a potential 
surgery is low. Another potential diagnostic procedure, which has already been used 
successfully in other soft tissue tumors and which is being currently tested, is ultrasound-
guided biopsy, a procedure generally performed under local anesthesia.  
Hysteroscopy and endometrial biopsy could be helpful to increase the rate of identification 
of sarcomas before surgery in patients with bleeding, even though leiomyosarcomas have 
been diagnosed only in about 35% and ESSs in 25% of cases undergoing endometrial 
biopsy.23  
In all cases of a growing ‘uterine’ mass or fibroid, especially in postmenopausal women 
without hormonal replacement therapy, a uterine sarcoma should be suspected and 
managed surgically. 
 
Methods of morcellation 
Morcellation is conducted using several techniques that should be meticulously 
discriminated during risk evaluation: 
 power morcellation of fibroid  
 power morcellation of the uterus  
 uterine morcellation during vaginal hysterectomy  
 morcellation with minilaparotomy incision 
 
 7 
 
What is the general impact of morcellation techniques? 
 potential dissemination of malignant cells through hematologic spread during 
manipulation with the specimen, which is a risk not influenced by morcellation, but 
rather by an indication for surgery 
 potential spread of malignant cells by seeding on the peritoneum during morcellation 
(sarcomatosis) 
 potential local spread/recurrence of the tumor after morcellation of the uterus 
during the vaginal approach (after a vaginal pure or a laparoscopic-assisted vaginal 
hysterectomy) 
 transecting the specimen into pieces will prevent the pathologist from adequately 
evaluating the specimen for size, invasion or resection margin status and thus stage 
cannot be properly determined 
 
What are the consequences in the shift from minimally invasive procedures to open 
procedures? 
Consequences additional to oncological outcomes should be mentioned. A Cochrane review 
of 4 495 patients undergoing hysterectomy for benign gynecological pathology provided a 
comparison between abdominal, laparoscopic and vaginal hysterectomy for complications, 
surgical time, length of hospital stay and out of work stay. Clear advantages were noted for 
the vaginal and laparoscopic approaches over abdominal hysterectomy.24 US data show that 
omitting the use of morcellation during hysterectomy can lead to a 99 000-day absent from 
work per year.17;25 Eight months after the FDA statement one report showed a decrease in 
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the use of laparoscopic hysterectomies by 4.1%, leading to an increase in major surgical 
complications from 2.2 to 2.8% and the rate of readmissions from 3.4 to 4.2%.26  
In Europe, based on Eurostat data, there are about 600 000 hysterectomies performed 
annually and the rate of laparoscopic hysterectomy relative to the total number of 
hysterectomies was about 20% in 2013.7 Long-term complications (e.g., additional 
reoperation, absence from work and scar herniation) requiring surgical repair will need to be 
included in any further evaluation of the impact in the shift of management. 
 
Are there surgical techniques that could be used to minimize the risks of tumor spread ? 
Most of the current techniques are considered preventive and based on expert opinion 
rather than on evidence-based data, the rarity of the entity.  The following precautions 
should help in minimizing the risks of tumor spread: 
 avoid unnecessary manipulation of the tumor by forceps 
 for morcellation, use specifically designed containers or an endobag for morcellation 
 take special care of necrotic fibroids, which are more vulnerable during manipulation 
 in case of a fibroid or uterus rupture perform peritoneal washings 
  total hysterectomy (laparoscopy-assisted vaginal hysterectomy, total laparoscopic 
hysterectomy) with en bloc resection is preferred over supracervical hysterectomy 
 
Further research should address the following key areas: 
 9 
 
 Improvements on the sensitivity and specificity of preoperative workup 
 more relevant statistical data on the risks of morcellation using specified registries, 
differentiating power and vaginal morcellation 
 modification of surgical techniques  
 modification of adjuvant therapy when morcellated sarcoma has been diagnosed 
 
Conclusions 
Uterine sarcomas are rare, aggressive tumors, with the majority of patients having a poor 
prognosis. Their prognosis could be iatrogenically negatively induced by morcellation in 
about 30% of all sarcomas (low-grade ESSs and adenosarcomas). Currently, the risk of having 
an unexpected sarcoma is about 1:352, but a proper preoperative examination can help to 
some extent in decreasing the number of unrecognized uterine sarcomas. An indication for 
myomectomy should be used only in patients with pregnancy plans; otherwise, en bloc 
hysterectomy is preferred in both symptomatic and postmenopausal patients, especially in 
those with a growing mass. Power morcellation has still its place in the armamentarium of 
gynecologic surgery, particularly for large fibroids undergoing myomectomy and the use of 
an endobag could be a safe option to prevent iatrogenic seeding of tumor cells.  
Rather than banning morcellation techniques altogether, attempts should be made to 
increase a proper preoperative workup, evaluate risk factors and develop techniques to 
decrease the risk of spillage. Proper informed consent is mandatory and patient preference 
should be a part of indication procedure. 
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Final recommendations 
- examination should be performed by an experienced ultrasonographist in patients  for 
whom myomectomy or hysterectomy with morcellation is considered, even though there 
are no fixed criteria for establishing sarcoma 
- avoid morcellation if there are suspicious ultrasonographic signs, fast growth within 3 
months and rapid postmenopausal growth 
- when planning a power morcellation, a preoperative endometrial biopsy with hysteroscopy 
should be mandatory 
- morcellation should not be used if there is a suspicion of a sarcoma or if a sarcoma is 
present after endometrial biopsy/resection for uterine bleeding. A hysterectomy with en-
bloc resection should be the standard approach (by laparotomy for a bulky uterus) 
- use power morcellation only for uterine fibroids rather than for the whole uterus, which 
could be extracted vaginally or by minilaparotomy 
- surgical removal of uterine fibroids by myomectomy should be morcellated in endobag 
containers 
- in case of morcellation in a patient with unrecognized sarcoma the patient should be 
reported to an online database designed to look at the follow-up of such patients 
- informed consent should state the following information:  
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 risk of dissemination of unknown malignancy by the manipulation of the 
uterus/fibroid exists in both techniques 
 risk of dissemination of unknown malignancy by power morcellation is higher when 
using laparoscopic techniques, but the exact relative risk is unclear. The worse 
estimates state that the risk of unrecognized sarcomas of surgically treated fibroids is 
1 case out of 352 procedures , and about 30% of these cases could have a prognosis 
worsened by power morcellation techniques, resulting in a risk of about 1/1 000 that 
morcellation could exacerbate the patient’s prognosis  
 risks of higher blood loss, prolonged recovery, infectious complications and hernias 
are more often associated with open procedures  
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